Cancer Biology & Medicine

Papers
(The TQCC of Cancer Biology & Medicine is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Eliminating cervical cancer: a global health imperative for women225
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy129
The Warburg effect drives dedifferentiation through epigenetic reprogramming69
A foundation model-enhanced CT radiomics signature for the noninvasive assessment of tertiary lymphoid structures and prediction of therapy benefit in gastric cancer57
Artificial intelligence in breast cancer: applications and advancements56
Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity53
Early-onset gastric cancer global burden profile, trends, and contributors52
Lactate drives immune resistance via a pharmaceutically reversible H3K18la-KIF20A-c-Myc-PD-L1 axis in hepatocellular carcinoma47
Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance46
Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer45
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up42
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer37
Click chemistry-driven tumor theranostics: recent advances, challenges, and future perspectives37
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies36
<italic>Bifidobacterium animalis</italic> suppresses melanoma progression and activates anti-tumor immunity by inhibiting YAP1 expression in CD8<sup>&#x002B;</sup> T cells33
Tumor-resident bacteria in gastrointestinal cancers: from regulatory mechanisms to clinical implications33
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer33
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente31
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis30
Lung cancer mortality trends in China from 2013 to 2021 and projections to 203029
Immune checkpoint inhibitors: breakthroughs in cancer treatment28
ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment28
Biological mechanism and immune response of MHC-II expression in tumor cells27
Cancer stem cells: a target for overcoming therapeutic resistance and relapse27
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC27
Chinese expert consensus on additional surgery following endoscopic resection for early colorectal cancer (2025 edition)25
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis25
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer25
Cancer cell-derived migrasomes harboring ATF6 promote breast cancer brain metastasis via endoplasmic reticulum stress-mediated disruption of the blood-brain barrier24
Non-coding RNA delivery via lipid nanoparticles: a novel strategy for cancer immunotherapy24
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival24
Effects of Helicobacter pylori eradication on the profiles of blood metabolites and their associations with the progression of gastric lesions: a23
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity22
Nodal peripheral T-cell lymphomas in the new classification systems22
Pyroptosis in cancer: a dual regulator of tumor cell fate and immune activation21
Enhancing cancer immunotherapy through polymer-based antibody conjugation technologies21
Mitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer21
Facing challenges with hope: universal immune cells for hematologic malignancies21
Human papillomavirus vaccination willingness under resource inequities: momentary intervention effects of an educational video20
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study19
Progress toward cervical cancer elimination: global disparities and China&#x2019;s contributions18
SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway17
Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies17
Expert consensus on the detection and clinical application of tumor mutational burden16
Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review16
From overtreatment to precision: a new clinical standard for DCIS management16
Evolution in single-cell proteomics drives new frontiers in cancer biology and precision medicine15
Biological insights in non-small cell lung cancer15
Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study15
Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice15
Elucidating the synergistic roles of CD4&#x002B; T and dendritic cells in antitumor immunity14
Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer14
Single-cell and spatial transcriptome analyses reveal tumor immunometabolism in lymph node metastasis of lung cancer14
Current and future trends in whole genome sequencing in cancer14
Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma14
First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects14
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer13
A quick and reliable image-based AI algorithm for evaluating cellular senescence of gastric organoids13
Advances in antibody-drug conjugates for urothelial carcinoma treatment13
Ferumoxytol triggers cancer ferroptosis via an NF-κB-driven IRONKILL mechanism13
Chromatin relaxation dynamics and histone PTMs in the early DNA damage response12
Treatment strategies for patients with HER2-positive gastric cancer12
From dichotomy to diversity: deciphering the multifaceted roles of tumor-associated macrophages in cancer progression and therapy12
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy12
PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas12
PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer12
The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer12
Liquid-liquid phase separation in DNA double-strand break repair12
Immunological and metabolic optimization of tumor neoantigen vaccines12
Anti-tumor pharmacology of natural products targeting mitosis11
Metabolic regulation of tumor-associated macrophage function and immunotherapy in cancer11
Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway11
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer11
Research progress in tumor angiogenesis and drug resistance in breast cancer11
Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer11
Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window11
Major roles of the circadian clock in cancer11
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibi11
Metabolic regulation of immune responses to cancer11
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer10
Induction immunochemotherapy followed by definitive radiotherapy in patients with limited-stage small cell lung cancer: a multicenter study10
Single-arm trials for domestic oncology drug approvals in China10
Lenvatinib triggers an EGR1-ZNF768-SLC7A11 adaptive response to limit ferroptosis-mediated therapeutic efficacy in hepatocellular carcinoma10
Effectiveness of postoperative adjuvant radiochemotherapy versus radiotherapy in thoracic esophageal squamous cell carcinoma with lymph node metastasis: a multicenter randomized study10
Current status of management of immune-related adverse events and practical needs for oncologist education10
Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications10
Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer10
Early detection of gastric cancer in China: progress and opportunities9
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy9
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer9
Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy9
MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB9
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification9
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer9
The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer9
Drug clinical trials on high-grade gliomas: challenges and hopes9
The evidence and concerns about screening ultrasound for breast cancer9
Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors9
Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation8
Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects8
Targeting PP2A for cancer therapeutic modulation8
Metabolic engineering of SLC38A2 reprograms glutamine utilization and enhances CAR-macrophage antitumor function in solid tumors8
Epigenetic regulators as the foundation for molecular classification of colorectal cancer8
Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism8
Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer8
Modeling cervical cancer elimination: a pathway to inform policy decisions8
Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer8
Microbiota-host interaction in colorectal cancer: emerging computational technology, multi-omics integration, and mechanisms8
Identifying occult high-risk features and stratified management strategies following curative resection for ampullary adenocarcinoma8
0.063655853271484